InvestorsHub Logo
Followers 420
Posts 2163
Boards Moderated 1
Alias Born 01/10/2013

Re: trebor4 post# 11442

Wednesday, 04/16/2014 11:22:50 PM

Wednesday, April 16, 2014 11:22:50 PM

Post# of 48316
What are you using as reference if you think 200 million is a few number of outstanding shares? IMO you are failing to take into account the need to fund multiple clinical trials with many more patients and clinical sites. As I mentioned previously, the CEO's statements are of little consequence as he should be willing to change his views based on the companies best interests. You should be more concerned with a CEO that forces his own agenda without fully considering the benefit of such a decision.